KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Share-based Compensation (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Share-based Compensation for 15 consecutive years, with $1000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Share-based Compensation fell 98.96% year-over-year to $1000.0, compared with a TTM value of $48000.0 through Sep 2025, down 86.52%, and an annual FY2024 reading of $264000.0, down 79.23% over the prior year.
  • Share-based Compensation was $1000.0 for Q2 2025 at TherapeuticsMD, down from $23000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $7.3 million in Q3 2021 and bottomed at $1000.0 in Q2 2025.
  • Average Share-based Compensation over 5 years is $1.7 million, with a median of $459500.0 recorded in 2023.
  • The sharpest move saw Share-based Compensation skyrocketed 141.86% in 2021, then crashed 98.96% in 2025.
  • Year by year, Share-based Compensation stood at $5.3 million in 2021, then plummeted by 43.9% to $3.0 million in 2022, then crashed by 96.11% to $116000.0 in 2023, then crashed by 79.31% to $24000.0 in 2024, then plummeted by 95.83% to $1000.0 in 2025.
  • Business Quant data shows Share-based Compensation for TXMD at $1000.0 in Q2 2025, $23000.0 in Q1 2025, and $24000.0 in Q4 2024.